Showing 1501-1510 of 3044 results for "".
- Novel Epigenetic Mechanism May Cause Drug Resistance in Melanomahttps://practicaldermatology.com/news/novel-epigenetic-mechanism-may-cause-drug-resistance-in-melanoma/2457634/New research sheds light on epigenetic reason for drug resistance in melanoma, and identifies potential therapies that may prevent such resistance, according to a paper in Nature Communications. Mount Sinai researchers identified a novel e
- "Phenomenal Gains" in Derm Device Market, Global Market Insights Predictshttps://practicaldermatology.com/news/phenomenal-gains-in-derm-device-market-global-market-insights-predicts/2457645/Dermatology devices market, an integral vertical of medical equipment space, of late, has been providing lucrative opportunities to the investors to exploit economies of scale. The claim is very well validated from the increasing attempts by the market giants to brainstorm innovative products tha
- New Applicator Suggests Cryolipolysis May Be an Option for Male Pseudogynecomastiahttps://practicaldermatology.com/news/new-applicator-suggests-cryolipolysis-may-be-an-option-for-male-pseudogynecomastia/2457678/Thanks to a conformable surface applicator, cryolipolysis can be a safe and effective way to treat male pseudogynecomastia, according to a recent study in Lasers in Surgery and Medicine (LSM). “This split-b
- Game On: Head-to-head Trials to Enhance Competition in PsO Markethttps://practicaldermatology.com/news/head-to-head-trials-to-enhance-competition-in-pso-market/2457684/An increase in head-to-head trials will enhance the competition within the psoriasis market, according to
- Trevi Therapeutics Appoints Yann Mazabraud as Chief Commercial Officerhttps://practicaldermatology.com/news/trevi-therapeutics-appoints-yann-mazabraud-as-chief-commercial-officer/2457685/Trevi Therapeutics, Inc. has named Yann Mazabraud as its Chief Commercial Officer and Head of International. Mr. Mazabraud will join Trevi’s senior management team and be responsible for overseeing Trevi’s commercial strategy and international operations.
- About 415 Million People May Have Rosacea Worldwidehttps://practicaldermatology.com/news/about-415-million-people-may-have-rosacea-worldwide/2457701/As many as 415 million people worldwide may have rosacea, according to new research in the British Journal of Dermatology. Dr. Jacob Thyssen and colleagues at the University of Copenhagen, Denmark, conducted
- Nanotechnology May Improve Onychomycosis, Cut Costshttps://practicaldermatology.com/news/nanotechnology-may-improve-onychomycosis-cut-costs/2457702/Nanotechnology can improve efinaconazole treatment for onychomycosis and make it more cost effective, according to new research in the Journal of Drugs in Dermatology.
- PAH after Cryolipolysis May Not Be So 'Rare'https://practicaldermatology.com/news/pah-after-cryolipolysis-may-not-be-so-rare/2457707/Paradoxical adipose hyperplasia (PAH) after cryolipolysis may be more common than previously thought according to a paper in the July issue of Plastic and Reconstructive Surgery®. While PAH can be treated successfully
- Michael Mazen Jafar is New Chief Marketing Officer at Evolushttps://practicaldermatology.com/news/michael-mazen-jafar-is-new-chief-marketing-officer-at-elovus/2457722/Evolus, Inc. has expanded its management team with the appointment of Michael Mazen Jafar as Chief Marketing Officer. Mr. Jafar joins Evolus from Allergan where he most recently served as Vice President, Medical Aesthetics. At Allergan Mr. Jafar led the commercial launch of Juve
- Older Melanoma Patients May Have Better Response to Immune Checkpoint Blockade Therapyhttps://practicaldermatology.com/news/older-melanoma-patients-may-have-better-response-to-immune-checkpoint-blockade-therapy/2457728/Patient age correlates with response to immunotherapy in melanoma, and depleting regulatory T cells in young patients may have a therapeutic potential to enhance response in younger patients, according to research from The Wistar Institute. Study resul